Edaravone, sold under the brand names Radicava and Radicava ORS, is a prescription treatment for amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease. It cannot cure ALS, reverse nerve damage, or magically return stubborn muscles to factory settings. However, research shows that it may slow the loss of physical function in some people with the disease.
Radicava is available as an intravenous infusion, while Radicava ORS is a liquid suspension that can be swallowed or administered through certain feeding tubes. Although both contain the same active ingredient, their doses, administration instructions, and daily logistics are different.
What Is Edaravone?
Edaravone is classified as a free-radical scavenger. Free radicals are unstable molecules that can contribute to oxidative stress, a process that may damage cells, including motor neurons. Scientists believe oxidative stress may play a role in ALS progression.
The precise way edaravone produces its therapeutic effect in ALS remains unknown. In plain English, researchers understand some of the chemistry, but the medication has not handed over its complete instruction manual. Its antioxidant activity may help limit oxidative damage to nerve cells, potentially slowing functional decline.
The U.S. Food and Drug Administration first approved intravenous Radicava in 2017. Radicava ORS, the oral suspension, was approved in 2022. The oral formulation was designed to produce drug exposure comparable to the IV formulation when taken under the required fasting conditions.
What Is Radicava Used For?
Radicava and Radicava ORS are FDA-approved for the treatment of amyotrophic lateral sclerosis. ALS is a progressive neurological disease that damages the motor neurons responsible for voluntary movement, speech, swallowing, and breathing.
Edaravone is intended to slow the decline in physical function. It is not considered a cure, and patients should not expect it to rebuild motor neurons that have already been lost. Treatment is usually part of a broader ALS care plan that may include riluzole, respiratory support, nutrition services, physical therapy, communication devices, mobility equipment, and symptom-specific medications.
What the clinical trial found
The pivotal study included 137 Japanese adults with relatively early ALS who retained substantial independence, had normal or near-normal respiratory function, and had been diagnosed within the previous two years. Most participants were also taking riluzole.
After 24 weeks, patients receiving edaravone had an average 5.01-point decline on the ALS Functional Rating Scale-Revised, or ALSFRS-R, compared with a 7.50-point decline among patients receiving placebo. The adjusted treatment difference was 2.49 points in favor of edaravone.
The ALSFRS-R measures abilities such as speaking, swallowing, handwriting, dressing, walking, turning in bed, climbing stairs, and breathing. A smaller drop indicates slower functional decline. However, the original trial studied a carefully selected group, so an individual patient’s response may be different. Evidence that edaravone extends survival is less certain than the evidence concerning functional decline.
Edaravone Dosing
Edaravone follows a cycle-based schedule rather than a simple “take one every day forever” routine. Marking treatment and drug-free days on a calendar can prevent confusion, especially after the initial cycle.
Radicava IV dosing
The recommended intravenous dose is 60 mg infused over 60 minutes. A full dose is administered using two consecutive single-dose bags, each containing 30 mg in 100 mL of solution.
- Initial cycle: One 60 mg infusion daily for 14 consecutive days, followed by 14 days without treatment.
- Later cycles: One 60 mg infusion daily on 10 days within a 14-day period, followed by 14 days without treatment.
The infusion should be stopped promptly if symptoms of a hypersensitivity reaction develop. Other medications must not be mixed into the Radicava infusion bags.
Radicava ORS dosing
The recommended oral dose is 105 mg, equal to 5 mL of suspension, taken in the morning by mouth or through an approved feeding tube. The same initial and subsequent treatment cycles used for the IV version apply to Radicava ORS.
- Initial cycle: 5 mL daily for 14 days, followed by 14 drug-free days.
- Later cycles: 5 mL daily on 10 of 14 days, followed by 14 drug-free days.
The bottle should be turned upside down and shaken vigorously for at least 30 seconds before the first use. Measure each dose with the supplied 5 mL oral syringe. A household teaspoon may look qualified for the job, but it is not an accurate medical measuring device.
Fasting requirements for Radicava ORS
Food can substantially reduce the amount of oral edaravone absorbed. Radicava ORS should be taken in the morning on an empty stomach, with no food for one hour afterward. Water is allowed.
- After a high-fat meal, wait at least 8 hours before taking the dose.
- After a low-fat meal, wait at least 4 hours.
- After a caloric supplement, such as a protein drink, wait at least 2 hours.
- After the dose, wait at least 1 hour before eating or consuming anything other than water.
Taking Radicava ORS with a high-fat meal can sharply lower drug exposure. The fasting instructions are therefore part of the dose, not optional fine print hiding at the bottom of the box.
Feeding tube administration
Radicava ORS may be given through compatible nasogastric or PEG tubes made from silicone, polyurethane, or polyvinyl chloride. The tube should be flushed with at least 1 ounce, or approximately 30 mL, of water before and after administration. Caregivers should follow the product instructions and the patient’s clinical nutrition plan.
What happens after a missed dose?
Do not take two doses the next day to make up for a missed Radicava ORS dose. Contact the prescribing team when uncertain about the schedule. Doses should not be taken during the designated drug-free days.
Common Side Effects of Edaravone
The most commonly reported adverse reactions in placebo-controlled IV studies were:
- Bruising or contusion
- Gait disturbance or increased difficulty walking
- Headache
In pooled clinical trials, bruising occurred in about 15% of edaravone-treated patients, gait disturbance in 13%, and headache in 10%. Fatigue was reported in approximately 7.6% of participants in a six-month open-label Radicava ORS study.
Other reported reactions included dermatitis, eczema, fungal skin infection, sugar in the urine, and respiratory problems. Because ALS itself can cause weakness, walking difficulties, fatigue, falls, and respiratory symptoms, determining whether a new problem comes from the medication or the disease may require clinical evaluation.
When to contact the care team
Call the prescribing clinician if headaches, fatigue, skin changes, bruising, or changes in walking become persistent, severe, or noticeably different from the patient’s usual ALS symptoms. A symptom diary can help the care team identify patterns tied to treatment days.
Serious Warnings and Allergic Reactions
Hypersensitivity and anaphylaxis
Edaravone can cause severe allergic reactions, including anaphylaxis. Reactions have occurred during treatment and after a dose was administered. Seek emergency medical care for symptoms such as:
- Hives, widespread redness, or an unusual rash
- Swelling of the face, lips, tongue, or throat
- Trouble breathing, wheezing, or difficulty swallowing
- Dizziness, fainting, or a sudden drop in blood pressure
Patients with a known allergy to edaravone or any ingredient in Radicava or Radicava ORS should not receive the medication.
Sulfite allergy warning
Both formulations contain sodium bisulfite. Sulfites can trigger allergic reactions, including potentially life-threatening anaphylaxis or asthma attacks. Sulfite sensitivity is more common among people with asthma, although it can also occur in those without asthma.
Before treatment begins, tell the healthcare team about asthma, medication allergies, food-related sulfite reactions, or previous unexplained episodes of wheezing and swelling.
Edaravone Drug and Food Interactions
The current prescribing information does not list a broad set of established, clinically significant drug-drug interactions. Edaravone is not expected to strongly inhibit or induce the major liver enzymes responsible for metabolizing many common medications.
In pharmacokinetic studies, oral edaravone did not meaningfully change exposure to sildenafil, rosuvastatin, or furosemide. Still, this does not prove that every possible combination is risk-free. Patients should provide their pharmacist and neurologist with a complete list of prescription drugs, over-the-counter products, vitamins, herbal remedies, and supplements.
The most important established interaction for Radicava ORS involves food. Eating too close to the dose can reduce absorption, especially after high-fat meals. IV Radicava does not have this food restriction, but no other medication should be injected into or mixed with its infusion bags.
Additional Precautions
Pregnancy
Adequate human pregnancy data are not available. Animal studies identified developmental risks, including reduced growth, delayed development, and fetal or offspring death at certain exposures. Anyone who is pregnant, may be pregnant, or plans to become pregnant should discuss potential benefits and risks with the prescribing neurologist.
Breastfeeding
It is unknown whether edaravone passes into human breast milk or affects milk production or a nursing infant. The decision to breastfeed during treatment should be made with the medical team after considering the parent’s treatment needs and possible risks to the child.
Children and older adults
Safety and effectiveness have not been established in pediatric patients. Clinical studies did not show major overall differences between older and younger adults, although some older patients may be more sensitive to treatment or its side effects.
Kidney and liver conditions
No dosage adjustment is recommended solely for mild or moderate kidney impairment. The effect of severe kidney impairment has not been adequately studied. Pharmacokinetic changes in people with liver impairment were not considered clinically significant, and the prescribing information does not recommend a liver-based dosage adjustment.
What Does Radicava Look Like?
Radicava is not a tablet or capsule, so searching for a pill imprint will lead nowhere useful.
Radicava IV appearance
The intravenous product is a clear, colorless solution supplied in single-dose polypropylene infusion bags. Each bag contains 30 mg of edaravone in 100 mL, and two bags are used for a complete 60 mg dose.
The bags are protected by specialized overwrap packaging with an oxygen absorber and indicator. Healthcare professionals should not use the product if the solution is discolored, contains particles, or the oxygen indicator suggests excessive oxygen exposure.
Radicava ORS appearance
Radicava ORS is an opaque, homogeneous liquid that is white to off-white. It is supplied in an amber glass bottle and contains 105 mg of edaravone per 5 mL.
Packaging, labels, and distribution cartons can change. Never identify a medication from an online picture alone. Confirm the product name, concentration, prescription label, expiration information, and pharmacy instructions before use.
Storage and Handling
Patients should store Radicava ORS upright at controlled room temperature, generally 68°F to 77°F, and protect it from light. Keep the bottle tightly closed.
After opening, discard unused suspension after 15 days or 30 days from the pharmacy shipment date printed on the carton label, whichever occurs first. A white crust may sometimes appear around the bottle neck during normal use; this does not necessarily mean the medication has spoiled.
IV bags require professional storage and protection from oxygen and light. Once the outer package is opened, the product must be used within the time specified by the manufacturer.
Practical Experiences With Radicava Treatment
Experiences with edaravone vary widely, but the biggest day-to-day issue is often not a dramatic side effect. It is the routine. ALS already turns ordinary activities into scheduled operations, and edaravone adds another calendar that must be followed accurately.
Consider a composite example of an adult beginning IV Radicava. During the first cycle, the patient attends 14 consecutive infusion appointments. The medication itself takes about an hour, but transportation, preparation, line access, observation, and the trip home can turn each infusion into a much larger block of the day. A caregiver may need to rearrange work, transportation, meals, and other appointments. Some patients find the routine reassuring because trained staff are present; others find repeated travel exhausting.
When that person transitions to Radicava ORS, the travel burden may shrink, but the morning routine becomes more precise. The family may place the dosing syringe, calendar, and medication log together in one clean location. The previous evening’s meal time matters because of the fasting requirement. Breakfast waits until at least one hour after the medicine. A simple phone alarm labeled “Radicava first, breakfast later” can prevent a half-awake bowl of cereal from disrupting the plan.
Hand weakness can make shaking the bottle for 30 seconds, holding the syringe, and drawing up exactly 5 mL difficult. In that situation, caregiver assistance is not a luxury; it is part of safe administration. Occupational therapists may also suggest ways to stabilize supplies or reduce strain. When swallowing becomes challenging, discussing feeding-tube administration early can avoid rushed decisions later.
Patients may wonder whether the drug is working because edaravone generally does not produce an obvious daily sensation. There is no reliable “I can feel my antioxidants clocking in” moment. Its purpose is to slow decline, which can be difficult to notice without measurements over time. Neurologists may track ALSFRS-R scores, respiratory function, weight, walking ability, speech, swallowing, and assistance needs. A stable ability can sometimes be meaningful even when it does not feel like a dramatic improvement.
Side-effect tracking is also useful. A diary might record headaches on dosing days, unusual bruising, skin symptoms, fatigue, falls, wheezing, and changes in breathing. This information helps the care team separate treatment-related patterns from ALS progression, infections, dehydration, sleep problems, or other medications.
Expectations matter. Edaravone is not a promise that ALS will stop progressing. A patient may continue to lose function while still receiving a meaningful treatment benefit if the decline is slower than it would have been without therapy. That idea can be emotionally frustrating because the benefit is measured against an invisible alternative.
Successful treatment therefore involves more than swallowing 5 mL or sitting through an infusion. It requires planning, honest discussions about goals, periodic reassessment, allergy awareness, caregiver support, and a realistic understanding of what slowing progression means. The best routine is the one that is medically appropriate, sustainable, and least disruptive to the patient’s quality of life.
Conclusion
Edaravone is an FDA-approved ALS medication available as Radicava IV infusion and Radicava ORS oral suspension. It may slow functional decline, but it does not cure ALS or restore function already lost. The IV formulation is given as 60 mg over one hour, while the oral formulation is taken as 105 mg, or 5 mL, under strict fasting conditions.
Common side effects include bruising, gait disturbance, headache, and fatigue. The most urgent risks are hypersensitivity, anaphylaxis, and sulfite-related allergic reactions, particularly among people with asthma. Choosing between IV and oral treatment should involve the neurologist, patient, caregivers, and pharmacist, with attention to swallowing, mobility, fasting routines, allergies, treatment goals, and daily quality of life.
